INSIGHTEC appoints Red Lorry Yellow Lorry as UK PR agency
May 27, 2016/in Industry News /by Emily Andrews
Red Lorry Yellow Lorry will provide INSIGHTEC with an awareness campaign targeting both patients and medical professionals.
We will see EVS at over $1 but only due
to a R/S. The R/S is needed (along with
other steps) to uplist.
In this eventuality, the stock will rock!
I agree with every word of yours Ofir,
let EMITF pay with what they can, thus
gaining time for the REAL bonanza to
come (as i dream it will) with these 2
Gems of companies!
Recent developments with InsighTec, Canada
approval, Siemens, UK events (as specified in
various posts) show that something BIG is
about to happen with this company.
My interest in EMITF lie in both
InsighTec and Gamida Cell.
IMHO InsighTec will bear fruit
earlier than Gamida Cell.
The major breakthrough for
InsighTec will come with US
FDA approval. With this happening,
the real 'action' will start.
Tech PR agency Red Lorry Yellow Lorry (RLYL) has been appointed as UK PR agency for Insightec. The firm was founded in Israel and provides MR-guided focused ultrasound, a non-invasive therapy platform that RLYL says is "transforming medicine". The agency will develop an awareness campaign targeting both patients and medical professionals to highlight Insightec's work in developing the technology.
TEL AVIV, Israel and LONDON, Feb. 11, 2015 (GLOBE NEWSWIRE) -- Top Image Systems Ltd. (Nasdaq:TISA) a leading ECM (Enterprise Content Management) and BPM (Business Process Management) solutions and MIP (Mobile Imaging Platform) provider, announced that Avoka, the digital transaction enablement company specializing in multi-channel engagement applications, is presenting its mobile-initiated loan application process at FinovateEurope using Avoka Transact. Avoka Transact integrates TIS' MobiENROLL services in order to retrieve information from ID documents in near real time.
TIS was the only supplier on the market to deliver Avoka quality capture capabilities that could enable their digital sales enablement platform to use HTML5 pages as a customer front end.
Obviously NOT the only supplier!
Market is more or less
yawning to the news!
That INSIGHTEC's Exablate Neuro System Has Been Approved
for Commercial Use in Canada
The Company holds approximately 89.9% of the share capital of Elbit Medical Technologies Ltd. (TASE:EMTC-M) (86.2% on a fully diluted basis) which, in turn, holds approximately 31.3% of the share capital in INSIGHTEC (26.6% on a fully diluted basis).
The Premier toured the Magnetic Resonance-guided Focused Ultrasound (MRgFUS) Lab at Toronto Western Hospital, which is benefiting from a $3 million Memorandum of Understanding that was signed during the mission.
The agreement, between Israeli-based Insightec and Ontario's University Health Network, will enable Insightec to provide technology to the University Health Network for clinical research and development. This partnership will contribute to making Ontario a world centre of excellence for research and training in the use of focused ultrasound technology and will help create new jobs in Ontario's life sciences sector.
"This is a major breakthrough in the treatment of Essential Tremor," said Andres Lozano, MD, Dan Family Professor and Chairman of Neurosurgery at Toronto Western Hospital, University of Toronto. "We are excited to offer our patients a new, minimally-invasive therapy to control their tremors and effectively treat their debilitating symptoms. The patients we have treated so far with this technique have had significant relief of their tremor and a very quick recovery with minimal adverse events", he emphasized.
"We are very pleased to have received this grant and know it will contribute to our broad clinical development plans for this year, which include the launch of a registration study for our lead program and early clinical stage work on our immuno-oncology candidate. The grant announced today is the largest amount we have been rewarded to date. We feel it is a clear demonstration of the Innovation Authority's ongoing confidence and trust in our important mission," said Dr. Yael Margolin, Gamida Cell's president and CEO.
from the Israeli Government
Non-dilutive funding will support further development of NiCord® for blood cancers, CordIn® for rare genetic diseases and NK cells for immune therapy of cancer
“This trial is the next step in using high intensity focused ultrasound to treat prostate cancer, and has the potential to offer patients a far less invasive procedure, which ultimately means far fewer side effects,“ said Mr Mathias Winkler consultant urologist at the Trust and co-investigator in the trial. “Should this trial be successful we hope that this type of treatment will be available to patients across the NHS and that it will vastly improve the quality of life for prostate cancer survivors,” he concluded.
INSIGHTEC congratulates the medical team at Imperial College Healthcare NHS Trust for performing the first MR-guided focused ultrasound treatment in the United Kingdom for prostate cancer. This treatment is part of a broader study aimed at proving the safety and efficacy of the treatment.